Aquestive (AQST) awards director 50,500 stock options at $3.99

Rhea-AI Filing Summary

Aquestive Therapeutics director Timothy E. Morris received a grant of 50,500 stock options. These options give him the right to buy 50,500 shares of common stock at an exercise price of $3.99 per share. The options expire on June 10, 2036.

All of the underlying shares vest on June 10, 2027, provided Mr. Morris remains in continuous service with the company through that date. This is a compensation-related award rather than an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MORRIS TIMOTHY E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to purchase)	50,500	$0.00	--

Holdings After Transaction: Stock Option (right to purchase) — 50,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 50,500 options Exercise price: $3.99 per share Underlying shares: 50,500 shares +3 more

6 metrics

Stock options granted 50,500 options Grant to director Timothy E. Morris

Exercise price $3.99 per share Stock option strike price

Underlying shares 50,500 shares Common stock underlying options

Vesting date June 10, 2027 100% of underlying shares vest

Expiration date June 10, 2036 Option term end

Total derivative holdings after grant 50,500 options Total options following transaction

Key Terms

Stock Option (right to purchase), conversion or exercise price, underlying security shares, continuous service, +1 more

5 terms

Stock Option (right to purchase) financial

"security_title: "Stock Option (right to purchase)""

conversion or exercise price financial

"conversion_or_exercise_price: "3.9900""

underlying security shares financial

"underlying_security_shares: "50500.0000""

continuous service financial

"subject to Mr. Morris' continuous service with the Issuer"

vesting date financial

"underlying shares vest June 10, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 11:43 AM Accepted by SEC EDGAR 06/12/2026 - 11:43 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORRIS TIMOTHY E

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$3.99	06/10/2026		A		50,500		06/10/2027(1)	06/10/2036	Common Stock	50,500	$0	50,500	D

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Morris' continuous service with the Issuer from the grant date through the applicable vesting date.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aquestive Therapeutics (AQST) disclose in this Form 4 filing?

Aquestive Therapeutics disclosed that director Timothy E. Morris received a grant of 50,500 stock options. These options are compensation, not an open-market trade, and allow him to purchase common shares at a fixed $3.99 exercise price until June 10, 2036.

How many stock options did Timothy E. Morris receive from Aquestive Therapeutics (AQST)?

Timothy E. Morris received 50,500 stock options from Aquestive Therapeutics. Each option covers one share of common stock, so the award relates to 50,500 underlying shares. All of these shares are subject to future vesting conditions before they can be exercised.

What is the exercise price and term of the new AQST stock options?

The stock options granted to Timothy E. Morris have an exercise price of $3.99 per share. They are exercisable until June 10, 2036, giving a long-term window to buy shares at that fixed price once the options vest in 2027.

When do Timothy E. Morris’s Aquestive Therapeutics (AQST) options vest?

All of Timothy E. Morris’s 50,500 options vest on June 10, 2027. Vesting is contingent on his continuous service with Aquestive Therapeutics from the grant date through that vesting date, aligning the award with ongoing board involvement and performance.

Is the AQST Form 4 transaction a stock purchase or sale in the market?

The AQST Form 4 reports an option grant, not a market purchase or sale. Morris received 50,500 stock options as compensation, with an exercise price of $3.99. No open-market cash transaction for common shares occurred in this filing.